TY - JOUR
T1 - Polyinosinic-polycytidylic acid is the most effective TLR adjuvant for SIV gag protein-induced t cell responses in nonhuman primates
AU - Park, Haesun
AU - Adamson, Lauren
AU - Ha, Tae
AU - Mullen, Karl
AU - Hagen, Shoko I.
AU - Nogueron, Arys
AU - Sylwester, Andrew W.
AU - Axthelm, Michael K.
AU - Legasse, Al
AU - Piatak, Michael
AU - Lifson, Jeffrey D.
AU - McElrath, Juliana M.
AU - Picker, Louis J.
AU - Seder, Robert A.
PY - 2013/4/15
Y1 - 2013/4/15
N2 - Prime-boost immunization with heterologous vaccines elicits potent cellular immunity. In this study, we assessed the influence of various TLR ligands on SIV Gag-specific T cell immunity and protection following prime-boost immunization. Rhesus macaques (RMs) were primed with SIV Gag protein emulsified in Montanide ISA51 with or without TLR3 (polyinosinic-polycytidylic acid [poly-IC]), TLR4 (monophosphoryl lipid A), TLR7/8 (3M-012), TLR9 (CpG), or TLR3 (poly-IC) combined with TLR7/8 ligands, then boosted with replication defective adenovirus 5 expressing SIV Gag (rAd5-Gag). After priming, RMs that received SIV Gag protein plus poly-IC developed significantly higher frequencies of SIV Gag-specific CD4+ Th1 responses in blood and bronchoal-veolar lavage (BAL) fluid lymphocytes compared with all other adjuvants, and low-level SIV Gag-specific CD8+ T cell responses. After the rAd5-Gag boost, the magnitude and breadth of SIV Gag-specific CD8+ T cell responses were significantly increased in RM primed with SIV Gag protein plus poly-IC, with or without the TLR7/8 ligand, or CpG. However, the anamnestic, SIV Gag-specific CD8+ T cell response to SIVmac251 challenge was not significantly enhanced by SIV Gag protein priming with any of the adjuvants. In contrast, the anamnestic SIV Gag-specific CD4+ T cell response in BAL was enhanced by SIV Gag protein priming with poly-IC or CpG, which correlated with partial control of early viral replication after SIVmac251 challenge. These results demonstrate that prime-boost vaccination with SIV Gag protein/poly-IC improves magnitude, breadth, and durability of CD4+ T cell immune responses, which could have a role in the control of SIV viral replication.
AB - Prime-boost immunization with heterologous vaccines elicits potent cellular immunity. In this study, we assessed the influence of various TLR ligands on SIV Gag-specific T cell immunity and protection following prime-boost immunization. Rhesus macaques (RMs) were primed with SIV Gag protein emulsified in Montanide ISA51 with or without TLR3 (polyinosinic-polycytidylic acid [poly-IC]), TLR4 (monophosphoryl lipid A), TLR7/8 (3M-012), TLR9 (CpG), or TLR3 (poly-IC) combined with TLR7/8 ligands, then boosted with replication defective adenovirus 5 expressing SIV Gag (rAd5-Gag). After priming, RMs that received SIV Gag protein plus poly-IC developed significantly higher frequencies of SIV Gag-specific CD4+ Th1 responses in blood and bronchoal-veolar lavage (BAL) fluid lymphocytes compared with all other adjuvants, and low-level SIV Gag-specific CD8+ T cell responses. After the rAd5-Gag boost, the magnitude and breadth of SIV Gag-specific CD8+ T cell responses were significantly increased in RM primed with SIV Gag protein plus poly-IC, with or without the TLR7/8 ligand, or CpG. However, the anamnestic, SIV Gag-specific CD8+ T cell response to SIVmac251 challenge was not significantly enhanced by SIV Gag protein priming with any of the adjuvants. In contrast, the anamnestic SIV Gag-specific CD4+ T cell response in BAL was enhanced by SIV Gag protein priming with poly-IC or CpG, which correlated with partial control of early viral replication after SIVmac251 challenge. These results demonstrate that prime-boost vaccination with SIV Gag protein/poly-IC improves magnitude, breadth, and durability of CD4+ T cell immune responses, which could have a role in the control of SIV viral replication.
UR - http://www.scopus.com/inward/record.url?scp=84876001825&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876001825&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.1202958
DO - 10.4049/jimmunol.1202958
M3 - Article
C2 - 23509365
AN - SCOPUS:84876001825
SN - 0022-1767
VL - 190
SP - 4103
EP - 4115
JO - Journal of Immunology
JF - Journal of Immunology
IS - 8
ER -